Dr Kimme Hyrich MD PhD FRCPC

Photograph of Kimme Hyrich

Reader in Rheumatic Disease Epidemiology

Arthritis Research UK Centre for Epidemiology
Centre for Musculoskeletal Research
Institute of Inflammation and Repair
The University of Manchester
Manchester Academic Health Science Centre
Room 2.809 Stopford Building
Oxford Road
Manchester
M13 9PT
 

Role

I am a Reader in Rheumatic Disease Epidemiology in the Arthritis Research UK Centre for Epidemiology, part of the Centre for Musculoskeletal Research. My  main research interests are in the short and longterm outcomes in adult and childhood inflammatory arthritis, including a greater understanding of the role treatments play in these outcomes.

I am also an Honorary Rheumatology Consultant at the Kellgren Centre for Rheumatology, part of the  Central Manchester Foundation Trust.

Additional roles include Deputy Director for the MRes Medical Sciences (for intercalatintg medical students) and Epidemiology Module Lead for the MSc in Clinical Rheumatology.

Memberships of Committees and Professional Bodies

Methodological Knowledge

Epidemiology and biostatistics including analysis of longterm observational cohort studies.

Teaching

  • Supervision of higher level degress (MRes, MSc and PhD)
  • Manchester Medical School - Academic Advisor
  • MRes in Medical Sciences - Deputy Programme Director
  • Epidemiology Module Lead - MSc in Clinical Rheumatology

Biography

I completed my Bachelors of Science and medical degree at the University of Manitoba in Canada. This was followed by training in internal medicine in Winnipeg, Canada and a fellowship in rheumatology at the University of Toronto. I subsequently worked as an Arthritis Society of Canada/CIHR Research Fellow at the Arthritis Research UK (formerly arc) Epidemiology Unit in Manchester, being awarded my PhD in 2005. I am currently a Reader in Rheumatic Disease Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary, Manchester, UK.

My main research interests centre on outcomes in inflammatory arthritis, with a particular focus on pharmacoepidemiology. I am a principal investigator for the British Society for Rheumatology Biologics Register (BSRBR), which is prospectively collecting information on all patients receiving biologic therapy for a rheumatic disease throughout the United Kingdom. Work from this project has assessed the real-world efficacy of anti-TNF agents for rheumatoid arthritis as well as predictors of response and the risk of adverse events, including infection and myocardial infarction. My research in paediatrics includes the Childhood Arthritis Prospective Study (CAPS), an inception cohort which is studying both short and long-term outcomes in children diagnosed in the UK with juvenile idiopathic arthritis and 2 biologic registers in children: the Arthritis Research UK funded Safety and Efficacy of Biologics in Children (Extended Biologics Study) and the BSPAR Etanercept Register, which is focusing on the short and long-term safety of the use of biologic drugs in children with arthritis.

I supervise a number of PhD and Masters students working on these and other projects.

Qualifications

  • Bachelor of Science (1992) - University of Manitoba, Canada
  • MD (1996) - University of Manitoba, Canada
  • Fellow of the Royal College of Physicians of Canada (General Medicine and Rheumatology) - 2000
  • PhD (2005) - University of Manchester, UK

Collaborators and affiliated staff

  • Deborah Symmons (Manchester)
  • Anne Barton (Manchester)
  • Wendy Thomson (Manchester)
  • Michael Beresford (Liverpool)
  • Eileen Baildam (Liverpool)
  • Lucy Wedderburn (London)
  • Joyce Davidson (Glasgow)
  • Helen Foster (Newcastle)
  • Kath Watson (Manchester)
  • Chris Deighton (Derby)
  • Anja Strangfeld (Berlin)
  • Angela Zink (Berlin)
  • Johan Askling (Stockholm)
  • Loreto Carmona (Madrid)

Selected publications

2014

  • Bluett, et al (2014). Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J, 14(2), 171-175. eScholarID:201863 | PMID:23856853 | DOI:10.1038/tpj.2013.26
  • Mathews, R., Robinson, J., Battellino, M., Wong, C., Taylor, J., , B., Eyre, S., Churchman, S., Wilson, A., Isaacs, J., Hyrich, K., Barton, A., Plant, D., Savic, S., Cook, G., Sarzi-Puttini, P., Emery, P., Barrett, J., Morgan, A. & McDermott, M (2014). Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis, 73(6), 1202-1210. eScholarID:197153 | PMID:23687262 | DOI:10.1136/annrheumdis-2013-203276
  • Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. & Hyrich, K (2014). Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis, [Epub ahead of print], eScholarID:223617 | PMID:24685910 | DOI:10.1136/annrheumdis-2013-204851
  • Silva-Fernandez, L. & Hyrich, K (2014). Rheumatoid arthritis: When TNF inhibitors fail in RA-weighing up the options. Nat Rev Rheumatol, 10(5), 262-264. eScholarID:221933 | PMID:24614594 | DOI:10.1038/nrrheum.2014.34
  • Z├ívada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & , B (2014). The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Ann Rheum Dis, 73(1), 252-255. eScholarID:197157 | PMID:23644671 | DOI:10.1136/annrheumdis-2012-203102

2013

  • Coates, L., Tillett, W., Chandler, D., Helliwell, P., Korendowych, E., Kyle, S., McInnes, I., Oliver, S., Ormerod, A., Smith, C., Symmons, D., Waldron, N. & McHugh, N (2013). The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford), 52(10), 1754-1757. eScholarID:206101 | PMID:23887065 | DOI:10.1093/rheumatology/ket187
  • Cui, et al (2013). Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genet, 9(3), e1003394. eScholarID:191611 | PMID:23555300 | DOI:10.1371/journal.pgen.1003394
  • Fu, B., Lunt, M., Galloway, J., Dixon, W., Hyrich, K. & Symmons, D (2013). A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients. J Biopharm Stat, 23(2), 461-76. eScholarID:188652 | PMID:23437951 | DOI:10.1080/10543406.2011.616973
  • Galloway, J., Mercer, L., Moseley, A., Dixon, W., Ustianowski, A., Helbert, M., Watson, K., Lunt, M., Hyrich, K. & Symmons, D (2013). Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 72(2), 229-234. eScholarID:160338 | PMID:22532633 | DOI:10.1136/annrheumdis-2011-201108
  • Humphreys, J., Verstappen, S., Hyrich, K., Chipping, J. & Symmons, D (2013). 2010 ACR/EULAR classification criteria for rheumatoid arthritis predict increased mortality in patients with early arthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford), 52(6), 1141-1142. eScholarID:191607 | PMID:23463807 | DOI:10.1093/rheumatology/ket113
  • Humphreys, J., Verstappen, S., Hyrich, K., Chipping, J., Marshall, T. & Symmons, D (2013). The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis, 72(8), 1315-1320. eScholarID:168362 | PMID:22945499 | DOI:10.1136/annrheumdis-2012-201960
  • Hyrich, K. & Verstappen, S (2013). Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford), [Epub ahead of print], eScholarID:216516 | PMID:24352337 | DOI:10.1093/rheumatology/ket409
  • Low, A. & Hyrich, K (2013). Evaluating the Real-world Benefits and Risks of Anti-Tumor Necrosis Factor Therapies. J Rheumatol, 40(1), 4-6. eScholarID:186038 | PMID:23280161 | DOI:10.3899/jrheum.121260
  • McErlane, F., Beresford, M., Baildam, E., Chieng, S., Davidson, J., Foster, H., Gardner-Medwin, J., Lunt, M., Wedderburn, L., Thomson, W., Hyrich, K. & Childhood_Arthritis_Prospective_Study_(CAPS), C (2013). Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis, 72(12), 1983-1988. eScholarID:186037 | PMID:23256951 | DOI:10.1136/annrheumdis-2012-202031
  • McErlane, F., Beresford, M., Baildam, E., Thomson, W. & Hyrich, K (2013). Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatology (Oxford), 52(11), 1941-1951. eScholarID:193908 | PMID:23630368 | DOI:10.1093/rheumatology/ket150
  • McErlane, F., Foster, H., Davies, R., Lunt, M., Watson, K., Symmons, D. & Hyrich, K (2013). Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), [Epub ahead of print], eScholarID:206102 | PMID:23873820 | DOI:10.1093/rheumatology/ket248
  • Mercer, L., Davies, R., Galloway, J., Low, A., Lunt, M., Dixon, W., Watson, K., Symmons, D., Hyrich, K. & BSRBR_Control_Centre_Consortium, B (2013). Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford), 52(1), 91-98. eScholarID:186039 | PMID:23238979 | DOI:10.1093/rheumatology/kes350
  • Mercer, L., Low, A., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K. & BSRBR_Control_Centre_Consortium, B (2013). Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis, 72(1), 143-144. eScholarID:186021 | PMID:22843488 | DOI:10.1136/annrheumdis-2012-201814

2012

  • Plant, D., Ibrahim, I., Lunt, M., Eyre, S., Flynn, E., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J. & Barton, A (2012). Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumour necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther, 14(5), R214. eScholarID:176063 | PMID:23039402 | DOI:10.1186/ar4052
  • Plant, D., Prajapati, R., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J., BRAGGSS, B. & Barton, A (2012). Investigation of established rheumatoid-arthritis (RA) susceptibility genetic markers as predictors of response to anti-TNF therapy in a large UK cohort replicates association with the PTPRC gene. Arthritis Rheum, 64(3), 665-670. eScholarID:134295 | PMID:21952740 | DOI:10.1002/art.33381
  • Soliman, M., Hyrich, K., Lunt, M., Watson, K., Symmons, D. & Ashcroft, D (2012). Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. J Rheumatol, 39(2), 240-246. eScholarID:152346 | PMID:22174201 | DOI:10.3899/jrheum.110610
  • Soliman, M., Hyrich, K., Lunt, M., Watson, K., Symmons, D. & Ashcroft, D (2012). Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken), 64(8), 1108-1115. eScholarID:157945 | PMID:22422731 | DOI:10.1002/acr.21663

2009

  • Bowes, J, Potter, C, Gibbons, LJ, Hyrich, KL, Plant, D, BRAGGSS, Morgan, A, Wilson, A, Isaacs, J, Worthington, J, Barton, A. (2009). Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics, 19(4), 319-323. eScholarID:1d19079 | DOI:10.1097/FPC.0b013e328328d51f
  • Harrison MJ, Dixon WG, Watson KD, King YE, Groves R, Hyrich KL, Symmons D, BSRBR Control Centre Consortium. (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 68(2), 209-215. eScholarID:1d17129 | DOI:10.1136/ard.2007.087288

View all publications